Therini Bio, Inc. was founded with the core mission of developing innovative therapeutics to treat neuroinflammatory diseases caused by vascular dysfunction. The company's vision is to halt chronic neuroinflammation and neuronal damage through cutting-edge biotechnological research. Therini Bio focuses on creating immunotherapies that selectively target toxic fibrin deposits, which are known to trigger inflammation cascades in severe neurological and retinal diseases. Their market focus includes a range of inflammatory diseases, with a particular emphasis on conditions like Alzheimer's disease.

Notable affiliated individuals include leading scientists and researchers in the field of neuroinflammation and vascular biology. The company has attracted significant attention from investors due to its pioneering approach and promising clinical-stage pipeline. Key achievements include the development of novel therapeutic candidates that have shown potential in preclinical studies. Therini Bio's impact lies in its potential to transform the treatment landscape for neuroinflammatory diseases, offering hope for improved patient outcomes.